MCID: DMY004
MIFTS: 53

Demyelinating Disease malady

Categories: Neuronal diseases

Aliases & Classifications for Demyelinating Disease

Aliases & Descriptions for Demyelinating Disease:

Name: Demyelinating Disease 12 14
Demyelinating Diseases 52 42 69
Demyelinating Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3213
MeSH 42 D003711
NCIt 47 C34527
ICD10 33 G37.9
UMLS 69 C0011303

Summaries for Demyelinating Disease

MalaCards based summary : Demyelinating Disease, also known as demyelinating diseases, is related to multiple sclerosis, disease progression, modifier of and central pontine myelinolysis. An important gene associated with Demyelinating Disease is MBP (Myelin Basic Protein), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Natalizumab and Mitoxantrone have been mentioned in the context of this disorder. Affiliated tissues include t cells, brain and spinal cord, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Wikipedia : 71 A demyelinating disease is any disease of the nervous system in which the myelin sheath of neurons is... more...

Related Diseases for Demyelinating Disease

Diseases related to Demyelinating Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 261)
id Related Disease Score Top Affiliating Genes
1 multiple sclerosis, disease progression, modifier of 11.1
2 central pontine myelinolysis 11.0
3 balo concentric sclerosis 11.0
4 hypomyelination, global cerebral 10.9
5 leukodystrophy, adult-onset, autosomal dominant 10.7
6 multiple sclerosis 3 10.6
7 multiple sclerosis 5 10.6
8 megalencephalic leukoencephalopathy with subcortical cysts 10.6
9 neuromyelitis optica 10.5
10 adrenoleukodystrophy 10.4
11 crest syndrome 10.4 AQP4 IFNB1 MBP
12 intussusception 10.4 IL1B TNF
13 benign exophthalmos syndrome 10.4 IFNA1 IFNB1
14 lipomatosis, multiple symmetric 10.4 CD40LG MBP MOG
15 cervical adenoid basal carcinoma 10.4 IL1B MBP MOG
16 acute transverse myelitis 10.4
17 spinal polio 10.4 CD40LG MBP
18 urea cycle disorder 10.4 AQP4 IL1B MBP
19 benjamin syndrome 10.4 CD40LG CXCL10 MBP
20 dermatitis herpetiformis 10.4 CD40LG IL17A TNF
21 cerebellar liponeurocytoma 10.4 CD40LG MBP TNF
22 dysplastic nevus syndrome 10.4 CD40LG CXCL10 IL17A
23 temtamy syndrome 10.4 CD40LG CXCL10 MOG
24 clear cell adenoma 10.3 AQP4 IFNB1 MBP MOG
25 human immunodeficiency virus infectious disease 10.3 CD40LG IL1B TNF
26 central sleep apnea 10.3 CD40LG ICAM1 IL17A
27 niemann-pick disease 10.3 AQP4 IL17A MBP MOG
28 alopecia-intellectual disability syndrome 10.3 CXCL10 MBP MOG PLP1
29 cryptococcosis 10.3 CD40LG IL17A TNF
30 sexual masochism 10.3 CXCL10 IFNB1 TNF
31 dextrocardia 10.3 CD40LG IL1B TNF
32 early yaws 10.3 CD40LG IL1B MBP
33 gastroduodenal crohn's disease 10.3 CD40LG IL1B TNF
34 schwannoma of twelfth cranial nerve 10.3 AQP4 CD40LG MBP MOG
35 motility-related diarrhea 10.3 CCL2 IL1B TNF
36 ulcerative proctitis 10.3 CCL2 CCL3 TNF
37 intracranial arteriosclerosis 10.3 MBP SPP1 TNF
38 gastric dilatation 10.3 AQP4 IL17A MBP TNF
39 mineral metabolism disease 10.3 CD40LG IL1B TNF
40 keratoconus 10.3 IL17A IL1B TNF
41 central nervous system lymphoma 10.3 CCL2 IL1B TNF
42 endobronchial lipoma 10.3 AQP4 CD40LG IFNB1 MOG
43 dermatomycosis 10.3 CD40LG ICAM1 TNF
44 wound botulism 10.3 CD40LG IL1B TNF
45 breast adenomyoepithelioma 10.3 CXCL10 IL1B MMP9
46 leydig cell hypoplasia 10.3 MBP SPP1 TNF
47 ovarian cystic teratoma 10.3 CD40LG IL1B TNF
48 choroiditis 10.3 CCL2 IL1B TNF
49 choreatic disease 10.3 CD40LG MBP TNF
50 nerve fibre bundle defect 10.3 AQP4 MBP MOG

Graphical network of the top 20 diseases related to Demyelinating Disease:



Diseases related to Demyelinating Disease

Symptoms & Phenotypes for Demyelinating Disease

GenomeRNAi Phenotypes related to Demyelinating Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CD40LG ICAM1 IL17A IL1B RTN4 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CD40LG ICAM1 IL17A IL1B NTF3 RTN4

MGI Mouse Phenotypes related to Demyelinating Disease:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.3 AQP4 CD40LG CXCL10 ICAM1 IFNB1 IFNG
2 homeostasis/metabolism MP:0005376 10.28 SPP1 TNF IL1B MBP MMP9 NTF3
3 immune system MP:0005387 10.28 AQP4 CCL2 CD40LG CXCL10 ICAM1 IFNB1
4 cellular MP:0005384 10.22 CD40LG CXCL10 ICAM1 IFNG MBP MMP9
5 mortality/aging MP:0010768 10.21 SPP1 TNF AQP4 CD40LG CXCL10 ICAM1
6 cardiovascular system MP:0005385 10.19 AQP4 CD40LG CXCL10 ICAM1 IFNG IL1B
7 nervous system MP:0003631 10.03 MBP MMP9 MOG NTF3 PLP1 RTN4
8 muscle MP:0005369 9.92 ICAM1 IFNG MMP9 MOG NTF3 PLP1
9 neoplasm MP:0002006 9.8 ICAM1 IFNB1 IFNG IL1B MMP9 SPP1
10 skeleton MP:0005390 9.61 IFNB1 IFNG IL17A IL1B MMP9 CD40LG
11 vision/eye MP:0005391 9.28 AQP4 ICAM1 IFNG MBP MMP9 MOG

Drugs & Therapeutics for Demyelinating Disease

Drugs for Demyelinating Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 609)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 189261-10-7
2
Mitoxantrone Approved, Investigational Phase 4,Phase 2,Phase 3 65271-80-9 4212
3
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147245-92-9 3081884
4
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2,Phase 1 145155-23-3
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
8
4-Aminopyridine Approved Phase 4,Phase 3,Phase 2 504-24-5 1727
9
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 145258-61-3 6438354
10
Menthol Approved Phase 4,Phase 1,Early Phase 1 2216-51-5 16666
11
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
12
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078 2978
13
Ethanol Approved Phase 4,Phase 3 64-17-5 702
14
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216503-57-0
15
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
16
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
17
Memantine Approved, Investigational Phase 4,Phase 2,Phase 3 19982-08-2 4054
18
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 69-65-8 453 6251
19
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
20
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
21
Etanercept Approved, Investigational Phase 4 185243-69-0
22
Methotrexate Approved Phase 4,Phase 3,Early Phase 1 1959-05-2, 59-05-2 126941
23
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
24
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
25
Glycerol Approved, Experimental Phase 4,Phase 2,Phase 3 56-81-5 753
26 Titanium dioxide Approved Phase 4,Phase 2 13463-67-7
27
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
28
Calcium carbonate Approved Phase 4 471-34-1
29
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
30
Gabapentin Approved, Investigational Phase 4,Phase 2 60142-96-3 3446
31
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
32
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 637568 5271565
33
Acetaminophen Approved Phase 4,Phase 1 103-90-2 1983
34
Cetirizine Approved Phase 4,Phase 1,Phase 2 83881-51-0 2678
35
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
36
Histamine Approved, Investigational Phase 4,Phase 2,Phase 1 75614-87-8, 51-45-6 774
37
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
38
Ranitidine Approved Phase 4 66357-59-3, 66357-35-5 3001055
39
Aspirin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 50-78-2 2244
40
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
41
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
42
Iron Approved Phase 4,Early Phase 1 7439-89-6 23925
43 Piracetam Approved Phase 4 7491-74-9
44
Donepezil Approved Phase 4,Phase 3 120014-06-4 3152
45
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Early Phase 1 50-02-2 5743
46
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 128794-94-5 5281078
47
Mycophenolic acid Approved Phase 4,Phase 2,Phase 3,Early Phase 1 24280-93-1 446541
48
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
49
Citalopram Approved Phase 4,Phase 3 59729-33-8 2771
50
Norepinephrine Approved Phase 4,Phase 2,Phase 3 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 1666)
id Name Status NCT ID Phase
1 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4
2 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4
3 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4
4 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4
5 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
6 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4
7 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4
8 Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Unknown status NCT02259361 Phase 4
9 Resistance Training and Amino Pyridine in Multiple Sclerosis Unknown status NCT02143167 Phase 4
10 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4
11 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
12 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4
13 Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up Unknown status NCT00289159 Phase 4
14 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4
15 Study Evaluating the Efficacy of Enbrel (Etanercept) in Subjects in Japan Completed NCT00503503 Phase 4
16 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4
17 Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4
18 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
19 Natalizumab Temporary Discontinuation Study Completed NCT02775110 Phase 4
20 Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy Completed NCT00336557 Phase 4
21 Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients Completed NCT02146534 Phase 4
22 MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia Completed NCT01556685 Phase 4
23 Rebif® Pregnancy Registry Completed NCT00338741 Phase 4
24 A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone® Completed NCT00239993 Phase 4
25 A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy Completed NCT00238654 Phase 4
26 Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. Completed NCT01623596 Phase 4
27 fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls Completed NCT00391352 Phase 4
28 A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis Completed NCT01216072 Phase 4
29 Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) Completed NCT01534182 Phase 4
30 Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Completed NCT01317004 Phase 4
31 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Completed NCT01201343 Phase 4
32 Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy Completed NCT01498887 Phase 4
33 AVONEX® Combination Trial - "ACT" Completed NCT00112034 Phase 4
34 The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial Completed NCT01034579 Phase 4
35 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns Completed NCT01930799 Phase 4
36 Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities Completed NCT01456416 Phase 4
37 A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 Completed NCT01578330 Phase 4
38 Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4
39 Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis Completed NCT00629642 Phase 4
40 Fingolimod Effect on Cytokine and Chemokine Levels Completed NCT02373098 Phase 4
41 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Completed NCT02142205 Phase 4
42 Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis Completed NCT00963833 Phase 4
43 Natalizumab De-escalation With Interferon Beta-1b Completed NCT01144052 Phase 4
44 Efficacy of Fish Oil in Multiple Sclerosis Completed NCT01842191 Phase 4
45 Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis Completed NCT00246324 Phase 4
46 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device Completed NCT01791244 Phase 4
47 Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif Completed NCT00317941 Phase 4
48 Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment Completed NCT00942214 Phase 4
49 A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Completed NCT01142466 Phase 4
50 Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis Completed NCT00492765 Phase 4

Search NIH Clinical Center for Demyelinating Disease

Cochrane evidence based reviews: demyelinating diseases

Genetic Tests for Demyelinating Disease

Anatomical Context for Demyelinating Disease

MalaCards organs/tissues related to Demyelinating Disease:

39
T Cells, Brain, Spinal Cord, Testes, Monocytes, Endothelial, Cerebellum

Publications for Demyelinating Disease

Articles related to Demyelinating Disease:

(show top 50) (show all 151)
id Title Authors Year
1
Presynaptic, release-regulating mGlu2 -preferring and mGlu3 -preferring autoreceptors in CNS: pharmacological profiles and functional roles in demyelinating disease. ( 26791341 )
2016
2
The role of growth factors as a therapeutic approach to demyelinating disease. ( 27016070 )
2016
3
Low Prevalence of Sleep Disorders in Demyelinating Disease in a Northern Tenerife Population. ( 26951408 )
2016
4
Germinoma Mimicking Tumefactive Demyelinating Disease in Pediatric Patients. ( 26811911 )
2016
5
Demyelinating disease: Novel markers for disease severity in neuromyelitis optica. ( 27020559 )
2016
6
The influence of gut-derived CD39 regulatory T cells in CNS demyelinating disease. ( 27519147 )
2016
7
The role of I+4 integrin in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease: an infectious animal model for multiple sclerosis (MS). ( 27803063 )
2016
8
Association between demyelinating disease and autoimmune rheumatic disease in a pediatric population. ( 27746022 )
2016
9
An Occult Malignancy Behind a Demyelinating Disease: POEMS Syndrome. ( 27790622 )
2016
10
FLT PET/CT in a Case of Demyelinating Disease. ( 27088385 )
2016
11
Comparison of Cerebrospinal Fluid Opening Pressure in Children With Demyelinating Disease to Children With Primary Intracranial Hypertension. ( 27909013 )
2016
12
Clinical-radiological-pathological spectrum of central nervous system-idiopathic inflammatory demyelinating disease in the elderly. ( 27760861 )
2016
13
Intractable Hiccup in Demyelinating Disease with Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibody. ( 27725560 )
2016
14
Demyelinating disease: NMO spectrum disorders: clinical or molecular classification? ( 26846455 )
2016
15
Eosinophilic CNS vasculitis can mimic demyelinating disease of the brain and spinal cord. ( 25646272 )
2015
16
Impaired growth of the cerebellum in pediatric-onset acquired CNS demyelinating disease. ( 26552732 )
2015
17
A Demyelinating Disease; What Lies Beneath? ( 26204979 )
2015
18
Elevated cerebrospinal fluid opening pressure in a pediatric demyelinating disease cohort. ( 25681000 )
2015
19
Demyelinating disease: Neurodegeneration distinguishes MS from NMO. ( 26503928 )
2015
20
Interferon-stimulated genes-essential antiviral effectors implicated in resistance to Theiler's virus-induced demyelinating disease. ( 26703877 )
2015
21
A case of tumor-like inflammatory demyelinating disease with progressive brain and spinal cord involvement. ( 26648435 )
2015
22
Methionyl-tRNA Formyltransferase (MTFMT) Deficiency Mimicking Acquired Demyelinating Disease. ( 26060307 )
2015
23
Hypoxia Inducible Factor-1I+ in Astrocytes and/or Myeloid Cells Is Not Required for the Development of Autoimmune Demyelinating Disease(,.) ( 26213713 )
2015
24
Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease. ( 26409478 )
2015
25
The immune response in the CNS in Theiler's virus induced demyelinating disease switches from an early adaptive response to a chronic innate-like response. ( 26260496 )
2015
26
Demyelinating disease: Is TOPIC the last trial for clinically isolated syndrome? ( 25511890 )
2015
27
Regulatory and T Effector Cells Have Overlapping Low to High Ranges in TCR Affinities for Self during Demyelinating Disease. ( 26385521 )
2015
28
Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. ( 26516628 )
2015
29
Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis. ( 26496907 )
2015
30
Cerebral adrenoleukodystrophy: a demyelinating disease that leaves the door wide open. ( 26503938 )
2015
31
Vitamin D and estrogen synergy in Vdr-expressing CD4(+) T cells is essential to induce Helios(+)FoxP3(+) T cells and prevent autoimmune demyelinating disease. ( 26298324 )
2015
32
Elevation of AQP4 and selective cytokines in experimental autoimmune encephalitis mice provides some potential biomarkers in optic neuritis and demyelinating diseases. ( 26884844 )
2015
33
Rituximab therapy for ankylosing spondylitis associated to demyelinating disease of the central nervous system. ( 25776441 )
2015
34
Vitamin D in multiple sclerosis and central nervous system demyelinating disease--a review. ( 25985434 )
2015
35
Pain and spinal cord imaging measures in children with demyelinating disease. ( 26509120 )
2015
36
Dimethyl fumarate suppresses Theiler's murine encephalomyelitis virus-induced demyelinating disease by modifying the Nrf2-Keap1 pathway. ( 25721871 )
2015
37
The level of viral infection of antigen-presenting cells correlates with the level of development of Theiler's murine encephalomyelitis virus-induced demyelinating disease. ( 25428872 )
2015
38
Demyelinating disease: New study refutes link between vaccines and demyelination. ( 25385338 )
2014
39
Aquaporin-4 immuneglobulin g testing in 36 consecutive jamaican patients with inflammatory central nervous system demyelinating disease. ( 25309712 )
2014
40
Progression of Relapsing-Remitting Demyelinating Disease Does Not Require Increased TCR Affinity or Epitope Spread. ( 25267971 )
2014
41
Effect of the innate immune response on development of Theiler's murine encephalomyelitis virus-induced demyelinating disease. ( 24981833 )
2014
42
Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients. ( 25348720 )
2014
43
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease. ( 24718491 )
2014
44
Demyelinating disease: Mycophenolate mofetil-a viable treatment option for neuromyelitis optica? ( 25245150 )
2014
45
Neuroimaging of multiple sclerosis, acute disseminated encephalomyelitis, and other demyelinating diseases. ( 24342677 )
2014
46
Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler's murine encephalomyelitis virus-induced demyelinating disease. ( 25027060 )
2014
47
Primary central nervous system cytotoxic T-cell lymphoma mimicking demyelinating disease. ( 24881748 )
2014
48
Rituximab use in pediatric central demyelinating disease. ( 24768216 )
2014
49
Tumefactive demyelinating disease with isolated spinal cord involvement. ( 25298871 )
2014
50
No association between CCL2 gene polymorphisms and risk of inflammatory demyelinating diseases in a Korean population. ( 24786287 )
2014

Variations for Demyelinating Disease

Expression for Demyelinating Disease

Search GEO for disease gene expression data for Demyelinating Disease.

Pathways for Demyelinating Disease

Pathways related to Demyelinating Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 CCL2 CCL3 CCL4 CD40LG CXCL10 ICAM1
2
Show member pathways
13.73 CCL2 CCL3 CCL4 CD40LG CXCL10 IFNA1
3
Show member pathways
13.61 CCL2 CCL3 CCL4 ICAM1 IFNA1 IFNB1
4
Show member pathways
13.48 CCL2 CCL3 CCL4 CD40LG CXCL10 IL17A
5
Show member pathways
13.37 CCL2 CCL3 CCL4 CD40LG CXCL10 IL17A
6
Show member pathways
13.36 CCL2 CCL3 CCL4 CD40LG CXCL10 ICAM1
7
Show member pathways
12.93 CD40LG ICAM1 IFNA1 IFNG IL17A IL1B
8
Show member pathways
12.88 CCL2 CXCL10 ICAM1 IFNA1 IFNB1 IFNG
9
Show member pathways
12.82 CCL4 CXCL10 IFNA1 IFNB1 IFNG IL1B
10
Show member pathways
12.77 CCL2 CCL3 CCL4 CXCL10 IFNA1 IFNB1
11
Show member pathways
12.64 CCL2 IFNG IL17A IL1B TNF
12 12.61 CCL2 CD40LG CXCL10 IFNA1 IFNG IL17A
13
Show member pathways
12.58 ICAM1 IFNA1 IFNB1 IFNG TNF
14
Show member pathways
12.5 CD40LG IFNG IL17A IL1B TNF
15
Show member pathways
12.42 CCL2 CXCL10 IFNG IL17A IL1B MMP9
16
Show member pathways
12.4 CCL2 ICAM1 IFNG IL1B TNF
17 12.31 IFNA1 IFNB1 IFNG IL1B TNF
18
Show member pathways
12.29 CD40LG IFNG IL1B TNF
19
Show member pathways
12.27 CXCL10 IFNB1 IFNG IL1B TNF
20
Show member pathways
12.25 IFNA1 IFNB1 IFNG IL17A IL1B TNF
21 12.22 AQP4 IL1B PLP1 TNF
22 12.2 CCL2 ICAM1 IFNG IL1B MMP9 TNF
23 12.11 IFNB1 IFNG IL1B TNF
24
Show member pathways
12.09 CCL2 CCL3 CCL4 CXCL10
25 12.09 CCL2 ICAM1 IL17A IL1B MMP9 TNF
26
Show member pathways
12.05 CCL3 CCL4 IFNG IL1B
27 12.05 CCL2 CXCL10 ICAM1 IL1B MMP9 TNF
28
Show member pathways
12.02 IFNG IL17A IL1B TNF
29 12.01 CCL3 IFNB1 IFNG IL1B
30 11.98 CCL2 ICAM1 IL1B TNF
31 11.98 CCL4 CD40LG ICAM1 IL1B TNF
32 11.9 CCL3 CCL4 IFNG IL1B
33 11.89 CCL3 IFNG IL17A IL1B TNF
34 11.85 IFNB1 IFNG IL1B TNF
35
Show member pathways
11.83 CD40LG NTF3 TNF
36 11.82 CCL2 CCL3 ICAM1 IFNG IL17A IL1B
37
Show member pathways
11.78 CD40LG IFNG TNF
38
Show member pathways
11.75 CD40LG ICAM1 IFNG IL1B MMP9 TNF
39 11.74 CD40LG ICAM1 TNF
40 11.72 IFNA1 IFNB1 IFNG
41 11.65 IFNG SPP1 TNF
42 11.62 CCL2 IFNG IL1B TNF
43 11.62 CCL2 CD40LG ICAM1 IFNG IL1B TNF
44 11.59 IFNG IL1B SPP1 TNF
45 11.57 ICAM1 MMP9 TNF
46 11.56 IFNG IL1B TNF
47
Show member pathways
11.53 CCL3 CCL4 IFNG TNF
48 11.5 CCL2 CCL3 CCL4 IL1B MMP9 SPP1
49 11.49 CXCL10 ICAM1 IFNB1 IFNG IL1B
50 11.46 ICAM1 IFNG IL1B TNF

GO Terms for Demyelinating Disease

Cellular components related to Demyelinating Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 CCL2 CCL3 CCL4 CD40LG CXCL10 IFNA1
2 external side of plasma membrane GO:0009897 9.7 AQP4 CD40LG CXCL10 ICAM1 IFNG IL17A
3 extracellular space GO:0005615 9.47 CCL2 CCL3 CCL4 CD40LG CXCL10 ICAM1

Biological processes related to Demyelinating Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.99 CCL3 CXCL10 MMP9 NTF3
2 defense response to virus GO:0051607 9.99 CXCL10 IFNA1 IFNB1 IFNG
3 chemotaxis GO:0006935 9.98 CCL2 CCL3 CCL4 CXCL10
4 positive regulation of protein phosphorylation GO:0001934 9.97 IFNG IL1B MMP9 TNF
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 CCL2 CCL3 CCL4 ICAM1